| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d75d1a4caed60a9316608ed9c231546c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate |
1995-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a921109612fcdce97259cc38321e1e3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd6877a92b90a2f0c0f3098150a5aef0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d280d2553941880542bfd791e4add6b0 |
| publicationDate |
1999-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5874307-A |
| titleOfInvention |
Process for induction culture of cytotoxic T lymphocytes having killing activity against tumor cells |
| abstract |
A process for an induction culture of a cytotoxic T lymphocyte having cell killing activities against a tumor cell which comprises the step of coculturing a tumor tissue containing said tumor cell and a lymphocyte of autologous peripheral blood obtained from a subject from which the tumor tissue is derived. The process is convenient since no separation and pure culture of tumor cells is required. The resulting cytotoxic T lymphocyte cells are useful for clinical treatments of tumors, e.g. adoptive immunotherapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006204483-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6440735-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112831468-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004241162-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7572631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004224402-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020188435-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009137017-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7402307-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7977095-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7541184-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7824849-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009151182-A1 |
| priorityDate |
1994-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |